Trial intelligence / Profile preview

Metoclopramide + Granisetron for PONV in Orthognathic Surgery

NCT06454825Phase 4

Key facts

Status: Completed
Start: Apr 2020
Primary completion: Apr 2021
Countries: 1
Sponsor: Bezmialem Vakif University
Modality: Small Molecules

Drugs: metoclopramide
Conditions: postoperative nausea and vomiting (PONV)

Overview

Phase 4, randomised, double-blind trial of metoclopramide in postoperative nausea and vomiting (PONV) (2 arms), sponsored by Bezmialem Vakif University. Primary endpoint: Postoperative nausea and vomiting at 24 hours. Started Apr 2020; status: completed.

Design

2 arms

Study design: RandomizedDouble-blind

Granisetron Group
Received 3 mg granisetron IV.
Granisetron + Metoclopramide Group
Received 3 mg granisetron + 10 mg metoclopramide IV.

Endpoints

Primary

Postoperative nausea and vomiting24 hours

Secondary

Visual analogue scale24 hours
Systolic arterial pressureintraoperative
Diastolic arterial pressureintraoperative
Mean arterial pressureintraoperative
heart rateintraoperative
peripheral arterial saturationintraoperative
Rescue antiemetic24 hours
Bleeding amountintraoperative

Beyond the preview

Go deeper on NCT06454825.

Full results, competitive context and analysis are in the Gosset platform.

Full results & analysis

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT06454825.